Clinical trials
Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease clinical trials
Below are recruiting mild cognitive impairment (mci) due to alzheimer's disease clinical trials, each written for real people, not researchers. We’re tracking 61 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06761066Enrolling by invitation
Testing NVP-NK4146 for mild cognitive impairment due to Alzheimer's
This study tests a new medicine, NVP-NK4146, for people with mild cognitive impairment (MCI) due to Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
SeoulAges 60 years+ - NCT06254469RecruitingPhase 3
PET scan study for memory decline with head injury or Alzheimer's risk
This trial uses a special PET scan tracer to see if it can predict who will get worse over time. It is for people with mild memory or thinking problems that may be linked to past head injuries or early Alzheimer's disease.
Evanston, IllinoisAges 45 years+ - NCT06618807Recruiting
Infrared light for memory loss in mild cognitive impairment
This study tests whether shining a gentle infrared light on the head can help people with mild memory loss (MCI) improve their thinking and memory. It is designed for those who have mild cognitive impairment due to early Alzheimer's disease.
Toronto, OntarioAges 50 years+ - NCT06584357Recruiting
Digital and blood markers linked to brain scans in older adults
This study is looking for older adults (60–90) who are either cognitively normal, have mild cognitive impairment (MCI), or have mild-to-moderate Alzheimer's dementia. It aims to see how digital tests and blood-based markers relate to brain scans (amyloid and tau PET). You will need a study partner, undergo MRI and PET scans, and give blood samples.
Atlantis, FloridaAges 60–90 - NCT06548191RecruitingPhase 1
Time-Restricted Eating for Alzheimer's Disease
This study tests whether a time-restricted eating schedule (eating all meals within a 10-hour window each day) can improve memory and thinking in people with early Alzheimer's disease or mild cognitive impairment. Healthy partners of people with memory problems can also join as a comparison group.
San Diego, CaliforniaAges 60 years+ - NCT06529744Recruiting
Using blood tests to better diagnose early dementia
This study is testing whether simple blood tests can help doctors better understand the type and progression of memory or thinking problems in people with early dementia. It aims to improve confidence in the diagnosis and future outlook.
North York, OntarioAges 30–95 - NCT06379594Enrolling by invitation
Remote brain health clinic for mild memory problems
This study tests a remote 'brain health clinic' for people with mild memory or thinking problems (mild cognitive impairment). It aims to help diagnose the cause of memory issues from home, so you don't need to travel to a clinic.
London, Denmark HillAges 18 years+ - NCT05904132Recruiting
Brain stimulation therapy for early Alzheimer’s memory loss
This trial studies a “closed-loop” brain stimulation approach to improve symptoms in people with early Alzheimer’s-related memory problems. It may help by delivering stimulation based on your brain signals, if you meet the safety and diagnosis requirements.
Charlestown, MassachusettsAges 50–80 - NCT05795634Recruiting
Study stress effects in people at risk for Alzheimer’s
This study looks at how stress may affect thinking and memory in people with mild cognitive impairment (MCI) who are at risk for Alzheimer’s disease. You may be asked to do thinking tests and also involve a knowledgeable person who can report on changes over time.
Baltimore, MarylandAges 60 years+ - NCT05592678Recruiting
Study brain and memory test changes in Alzheimer’s or mild issues
This study looks at how well people with Alzheimer’s disease (AD) or mild cognitive impairment (MCI) perform on standardized memory/brain tests. It may help researchers understand changes over time, and whether certain types of brain signals or test results track with the condition.
San Antonio, TexasAges 65–100 - NCT05606341RecruitingPhase 1
Testing a diabetes-style shot to boost brain immunity in early Alzheimer’s
This Phase 1 study tests whether stimulating the immune system (through a receptor called TLR9) is safe and may affect brain changes in people with early Alzheimer’s. It mainly enrolls older adults with memory impairment confirmed by specific amyloid imaging.
New York, New YorkAges 60–85 - NCT03402919Recruiting
Brain and memory study for people with thinking changes
This study looks at memory and thinking changes using questionnaires, memory testing, and brain scans. It may help researchers better understand neurodegeneration and dementia and how these problems show up over time.
Calgary, AlbertaAges 50–90 - NCT04124029Recruiting
How head injuries affect brain health
This study looks at how mild or moderate head injuries (concussions) may relate to brain conditions like chronic traumatic encephalopathy (CTE) and Alzheimer's disease. By comparing people with and without head injuries, researchers hope to learn more about what causes brain changes over time.
Boston, MassachusettsAges 30–90 - NCT04123314RecruitingEarly Phase 1
Psilocybin study for depression in mild memory or early Alzheimer’s
This early-phase study tests whether psilocybin (a psychedelic substance) can help with depression in people who have mild memory problems or early Alzheimer’s. The trial also closely monitors safety, thinking changes, mood, and blood pressure before and after dosing.
Baltimore, MarylandAges 18–85 - NCT03174938Recruiting
BioFINDER 2 study for healthy aging and memory problems
This study uses brain scans and a spinal fluid test to better understand memory and thinking changes in different groups, from people with healthy thinking to early or established dementia. If you qualify, it may help researchers learn what’s driving these conditions and how they progress.
ÄngelholmAges 20–100 - NCT06883019Recruiting
Lecanemab for early onset inherited Alzheimer's
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
Beijing, ChinaAges 18–65 - NCT06099587Recruiting
Brain scan study for early Alzheimer's memory changes
This study uses a special MRI scan to look at the brain's memory center in people with early memory concerns. It aims to better understand changes that happen in the very early stages of Alzheimer's disease.
RennesAges 50–80 - NCT02811653Recruiting
Brain movement and memory study in early dementia
This study looks at how “slower movement” and brain changes relate to memory and thinking problems in people with early dementia (and some related conditions). It may help researchers understand what brain differences go with these symptoms, using tests and an MRI scan.
AmiensAges 40–85 - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Birmingham, AlabamaAges 50–90 - NCT07764146RecruitingPhase 1
Study of VY1706 for early Alzheimer's disease
This study tests an experimental treatment called VY1706 for people with early Alzheimer's disease. It aims to see if the treatment is safe and how well it works, and may help slow down the disease.
Maitland, FloridaAges 30–80 - NCT07214727RecruitingPhase 1
A study of ALN-5288 for Alzheimer's disease
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
MontrealAges 40–80 - NCT07094516RecruitingPhase 2
Testing VHB937 for early Alzheimer's disease
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Phoenix, ArizonaAges 50–85 - NCT06871839Recruiting
A study of lencanumab for early Alzheimer's disease
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
BeijingAges 50–90 - NCT05456503RecruitingPhase 3
PET scan study of tau buildup in memory and brain disorders
This Phase 3 study uses a PET/CT scan to measure whether a brain protein called tau (and related disease patterns) builds up in different dementia conditions. The goal is to better match which disorders have which brain changes and how they progress.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mild cognitive impairment (mci) due to alzheimer's disease?
- Yes. Clin2 currently lists 61 recruiting mild cognitive impairment (mci) due to alzheimer's disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mild cognitive impairment (mci) due to alzheimer's disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mild cognitive impairment (mci) due to alzheimer's disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.